Public BoD papers 26.5.22

Public meeting of the Board of Directors Thursday 28 th April at 12.45 pm By virtual means

Present: Chair: Chris Outram (CO), Chairman

Kathryn Riddle (KR), Non-executive director Dr Jane Maher (JM), Non-executive Director Robert Ainsworth (RA), Non-executive Director Prof Kieran Walshe (KW), Non-executive Director Grenville Page (GP), Non-executive Director Alveena Malik (AM), Non-executive Director Tarun Kapur (TK), Non-executive Director Prof Chris Harrison (CJH), Medical Director and Deputy CEO Bernie Delahoyde (BD), Chief Operating Officer Eve Lightfoot (EL), Director of Workforce Prof Janelle Yorke (JY), Executive Chief Nurse Dr Neil Bayman (NB), Executive Medical Director Sally Parkinson (SP), Interim Director of Finance Prof Richard Fuller (RF), Director of Education Prof Fiona Blackhall (FB), Director of Research Sue Mahjoob, Freedom to Speak Up Guardian Ed Smith - Clinical Director, Proton Beam Therapy Thomas Edwards - Interim Clinical Services Manager, PBT John Archer - Radiotherapy Services Manager David Lines - Principal clinical scientist, PBT treatment planning Sally Corbett - PBT MDT/Referral Coordinator Lara Hoing - PA & Admin Team Leader Matthew Redfern – Superintendent radiographer Danielle Delaney – Senior Radiographer Gillian Walsh – Paediatric Nurse, PBT Day Unit

Minutes: Louise Westcott (LW), Company Secretary In attendance: Jo D’Arcy, Assistant Company Secretary Mohammed Qureshi, Public Governor

Clinical presentation: Proton Beam Therapy Service - John Archer (JA), Tom Edwards (TE) and Dr Ed Smith (ES) JA introduced his team. TE is covering the role of clinical services manager. ES introduced the service and noted that we take patients from across the country and that patients are referred through a national portal. About 50% are paediatric. Planning takes place after an initial visit then 6 or 7 weeks of treatment. Patients stay in Central Manchester at a facility called Stay City. ES explained how the rooms work and where the beam flows into the rooms. The 4 th room is a research room. The sister centre has now opened in London. 50-60% of total patients will be randomised clinical trials at full ramp up. This is very high. There is an active outcomes programme, and we continue to collect data on these patients following treatment. Many of the patients we treat with PBT are rare tumours. A video tour was shown https://www.youtube.com/watch?v=1DjV4fvLMpU TE introduced the staff on the call and explained their roles. KR asked how the shuttle bus from the accommodation works and whether the patients have to wait for transport. TE noted that the bus is scheduled around the appointments and a shared resource with MFT. There’s a comfortable waiting area in the PBT building to take them home.

2